Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
|Videos|February 20, 2018
Caffeine Metabolism in PD
Author(s)Bobby Lazzara, MD
Lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data that support the neuro-protective properties of caffeine.
Advertisement
Published in the journal Neurology, an
The findings show serum levels of caffeine and metabolites were significantly decreased compared with controls (this was unrelated to total caffeine intake). In addition, serum caffeine levels were significantly decreased in patients with motor complications.
The authors concluded that lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data supporting caffeine as neuro-protective.
Advertisement
Related to this article
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5